Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 188489
                    [Title] => Innovative approach to high blood pressure treatment
                    [Summary] => Are you currently being treated for high blood pressure? If you are, it might alarm you to know that the results of blood pressure treatment programs worldwide are not very good despite all available drugs in the antihypertensive armamentarium.


In the United States (the country with the most available resources for health care), a 1997 report prepared by an expert committee stated that among people with high blood pressure, only 68 percent were aware they had such a condition and only 53 percent were receiving medical treatment. 


                    [DatePublished] => 2002-12-19 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 1767887
                    [AuthorName] => The Charter Bureau
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 167114
                    [Title] => BP drug launched
                    [Summary] => The research for an ideal blood-pressure (BP) lowering drug which is effective but with minimal side-effects is still on.


A unique drug called Preterax, based on the novel very-low-dose combination (VLCD) concept, was formally launched at the recent annual convention of the Philippine Heart Association (PHA) at the EDSA Shangri-La Hotel.


The symposium, organized in cooperation with leading pharmaceutical company Servier Phils., featured two internationally renowned speakers, both experts in the fields of high blood pressure and heart disease. 


                    [DatePublished] => 2002-07-04 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 167165
                    [Title] => BP drug launched
                    [Summary] => The research for an ideal blood-pressure (BP) lowering drug which is effective but with minimal side-effects is still on.


A unique drug called Preterax, based on the novel very-low-dose combination (VLCD) concept, was formally launched at the recent annual convention of the Philippine Heart Association (PHA) at the EDSA Shangri-La Hotel.


The symposium, organized in cooperation with leading pharmaceutical company Servier Phils., featured two internationally renowned speakers, both experts in the fields of high blood pressure and heart disease. 


                    [DatePublished] => 2002-07-04 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

PRETERAX

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 188489
                    [Title] => Innovative approach to high blood pressure treatment
                    [Summary] => Are you currently being treated for high blood pressure? If you are, it might alarm you to know that the results of blood pressure treatment programs worldwide are not very good despite all available drugs in the antihypertensive armamentarium.


In the United States (the country with the most available resources for health care), a 1997 report prepared by an expert committee stated that among people with high blood pressure, only 68 percent were aware they had such a condition and only 53 percent were receiving medical treatment. 


                    [DatePublished] => 2002-12-19 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 1767887
                    [AuthorName] => The Charter Bureau
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 167114
                    [Title] => BP drug launched
                    [Summary] => The research for an ideal blood-pressure (BP) lowering drug which is effective but with minimal side-effects is still on.


A unique drug called Preterax, based on the novel very-low-dose combination (VLCD) concept, was formally launched at the recent annual convention of the Philippine Heart Association (PHA) at the EDSA Shangri-La Hotel.


The symposium, organized in cooperation with leading pharmaceutical company Servier Phils., featured two internationally renowned speakers, both experts in the fields of high blood pressure and heart disease. 


                    [DatePublished] => 2002-07-04 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 167165
                    [Title] => BP drug launched
                    [Summary] => The research for an ideal blood-pressure (BP) lowering drug which is effective but with minimal side-effects is still on.


A unique drug called Preterax, based on the novel very-low-dose combination (VLCD) concept, was formally launched at the recent annual convention of the Philippine Heart Association (PHA) at the EDSA Shangri-La Hotel.


The symposium, organized in cooperation with leading pharmaceutical company Servier Phils., featured two internationally renowned speakers, both experts in the fields of high blood pressure and heart disease. 


                    [DatePublished] => 2002-07-04 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Innovative approach to high blood pressure treatment

By The Charter Bureau | December 19, 2002 - 12:00am

Are you currently being treated for high blood pressure? If you are, it might alarm you to know that the results of blood pressure treatment programs worldwide are not very good despite all available drugs in the...

Science and Environment

BP drug launched

July 4, 2002 - 12:00am

The research for an ideal blood-pressure (BP) lowering drug which is effective but with minimal side-effects is still on. A unique drug called Preterax, based on the novel very-low-dose combination (VLCD) concept,...

Science and Environment

BP drug launched

July 4, 2002 - 12:00am

The research for an ideal blood-pressure (BP) lowering drug which is effective but with minimal side-effects is still on. A unique drug called Preterax, based on the novel very-low-dose combination (VLCD) concept,...

Science and Environment